Cargando…

Development of Chemical Entities Endowed with Potent Fast-Killing Properties against Plasmodium falciparum Malaria Parasites

[Image: see text] One of the attractive properties of artemisinins is their extremely fast-killing capability, quickly relieving malaria symptoms. Nevertheless, the unique benefits of these medicines are now compromised by the prolonged parasite clearance times and the increasing frequency of treatm...

Descripción completa

Detalles Bibliográficos
Autores principales: Matralis, Alexios N., Malik, Adnan, Penzo, Maria, Moreno, Inmaculada, Almela, Maria J., Camino, Isabel, Crespo, Benigno, Saadeddin, Anas, Ghidelli-Disse, Sonja, Rueda, Lourdes, Calderon, Felix, Osborne, Simon A., Drewes, Gerard, Böesche, Markus, Fernández-Álvaro, Elena, Martin Hernando, Jose Ignacio, Baker, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2019
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6816013/
https://www.ncbi.nlm.nih.gov/pubmed/31566384
http://dx.doi.org/10.1021/acs.jmedchem.9b01099
Descripción
Sumario:[Image: see text] One of the attractive properties of artemisinins is their extremely fast-killing capability, quickly relieving malaria symptoms. Nevertheless, the unique benefits of these medicines are now compromised by the prolonged parasite clearance times and the increasing frequency of treatment failures, attributed to the increased tolerance of Plasmodium falciparum to artemisinin. This emerging artemisinin resistance threatens to undermine the effectiveness of antimalarial combination therapies. Herein, we describe the medicinal chemistry efforts focused on a cGMP-dependent protein kinase (PKG) inhibitor scaffold, leading to the identification of novel chemical entities with very potent, similar to artemisinins, fast-killing potency against asexual blood stages that cause disease, and activity against gametocyte activation that is required for transmission. Furthermore, we confirm that selective PKG inhibitors have a slow speed of kill, while chemoproteomic analysis suggests for the first time serine/arginine protein kinase 2 (SRPK2) targeting as a novel strategy for developing antimalarial compounds with extremely fast-killing properties.